Catalyst Pharmaceuticals Acquired by Angelini Pharma | Healthcare M&A Deal

Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals, a pharmacy business in Florida, for $4.1 billion. Angelini Pharma acquisitions expand into the U.S. market, while Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Catalyst Pharmaceuticals’ portfolio includes FDA-approved therapies for rare neuromuscular and neurological conditions, supporting Angelini’s brain health and rare disease strategy in FL acquisitions. The merger acquisition is a strategic acquisition by a strategic buyer, with boards approving the cash purchase price of $31.50 per share and expected closing in the third quarter of 2026, financed with support from BNP Paribas and involving Blackstone funds and select international partners.